[Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].

Abstract

PURPOSE:

Assess the efficacy of monoclonal antibody (daclizumab) therapy in the treatment of patients with non-infectious uveitis who do not respond to other immunosuppressive agents.

MATERIAL AND METHOD:

Ten patients with non-infectious intermediate and posterior uveitis were treated with intravenous daclizumab (humanized anti-IL-2 receptor monoclonal antibody) monthly for two years.

RESULTS:

70% of the patients have had some improvement in their inflammatory activity being maintained without recurrence. 10% of the patients improved their visual acuity in two lines and the macular edema decreased. 20% of the patients continued to have recurrences, but not worse than the year before. 40% of the patients gave up having the treatment with corticosteroids and 30% with minimum dose (5 mg). No secondary effects were noted during the treatment.

CONCLUSIONS:

Daclizumab is effective and safe for long-term use in the treatment of uveitis which cannot be kept under control by other treatments. In time, it allows the dose of corticosteroids to be decreased or even discontinued.

• Authors: M L Hernández Garfella, M Díaz Llopis, D Salom Alonso, E Cervera Taulet
• Journal: Archivos de la Sociedad Espanola de Oftalmologia (Arch Soc Esp Oftalmol) Vol. 79 Issue 12 Pg. 593-8 (Dec 2004) ISSN: 0365-6691 [Print] Spain
• Vernacular Title: Uveítis recurrentes y tratamiento con anticuerpos monoclonales (Daclizumab).
• PMID: 15627927 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Immunoglobulin G
• Immunosuppressive Agents
• Daclizumab

Topics

• Adolescent
• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Daclizumab
• Female
• Humans
• Immunoglobulin G (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Male
• Middle Aged
• Recurrence
• Uveitis (drug therapy)